Viatris announces u.s. fda tentative approval of a paediatric formulation of abacavir (abc)/dolutegravir (dtg)/lamivudine (3tc), a once-daily treatment for children living with hiv

Tentative approval will help enhance access to who-recommended paediatric regimen with the goal of improved adherence of hiv treatment for children in low- and middle-income countries pittsburgh and bangalore, india , sept. 5, 2023 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, today announced u.s. food and drug administration (fda) tentative approval for a new drug application for abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension for the treatment of hiv-1 infection in paediatric patients.
VTRS Ratings Summary
VTRS Quant Ranking